Andreas Wallnoefer

Andreas is a Partner and Investor at Jeito Capital. He has over 25 years of experience in the pharmaceutical and biotech industry, including 12 years as a member of the F. Hoffmann-La Roche Pharma (Roche) R&D Executive Leadership team, and five years as General Partner in the European venture capital firm, BioMedPartners.

As an investor, Andreas has successfully developed innovative companies and has been a board member of several European biotech companies. Prior to his career in venture capital, he was Head of Cardiovascular and Metabolism (CVM) R&D at Roche and a member of the Roche/Genentech Portfolio Committee. Andreas was part of several successful product developments and market introductions. Before the integration of Genentech (now a wholly owned member of The Roche Group), Andreas was Global Head of Clinical Research and Exploratory Development and led the R&D organization at multiple sites in Europe, the U.S., and Asia. He had a key role in the integration of the Roche and Genentech development organizations and subsequently led Roche’s Early Development Department.

Andreas holds a Ph.D. in Pharmacology from the University of Basel, degrees in Pharmaceutical Medicine, and was trained as a Clinical Research fellow at the Centre of Human Drug Research at the University Hospital of Leiden, Netherlands. He also holds an Executive M.B.A. from IMD Lausanne.